| Semaglutide and cardiovascular outcomes in patients with type 2 diabetes SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ... New England Journal of Medicine 375 (19), 1834-1844, 2016 | 5341 | 2016 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2319 | 2019 |
| The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients MC Riddle, J Rosenstock, J Gerich, ... Diabetes care 26 (11), 3080-3086, 2003 | 2186 | 2003 |
| Once-weekly semaglutide in adults with overweight or obesity JPH Wilding, RL Batterham, S Calanna, M Davies, LF Van Gaal, I Lingvay, ... New England Journal of Medicine 384 (11), 989-1002, 2021 | 2016 | 2021 |
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) JB Buse, J Rosenstock, G Sesti, WE Schmidt, E Montanya, JH Brett, ... The Lancet 374 (9683), 39-47, 2009 | 1959 | 2009 |
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea DM Kendall, MC Riddle, J Rosenstock, D Zhuang, DD Kim, MS Fineman, ... Diabetes care 28 (5), 1083-1091, 2005 | 1689 | 2005 |
| Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial FX Pi-Sunyer, LJ Aronne, HM Heshmati, J Devin, J Rosenstock, ... Jama 295 (7), 761-775, 2006 | 1615 | 2006 |
| Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1098 | 2019 |
| Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial J Rosenstock, M Tuchman, L LaMoreaux, U Sharma Pain 110 (3), 628-638, 2004 | 957 | 2004 |
| Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes JP Frías, MJ Davies, J Rosenstock, FC Pérez Manghi, L Fernández Landó, ... New England Journal of Medicine 385 (6), 503-515, 2021 | 937 | 2021 |
| Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial V Fonseca, J Rosenstock, R Patwardhan, A Salzman Jama 283 (13), 1695-1702, 2000 | 824 | 2000 |
| Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin J Rosenstock, SL Schwartz, CM Clark Jr, GD Park, DW Donley, ... Diabetes care 24 (4), 631-636, 2001 | 799 | 2001 |
| Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. J Rosenstock, E Ferrannini Diabetes care 38 (9), 1638-1642, 2015 | 746 | 2015 |
| A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with … J Rosenstock, M Davies, PD Home, J Larsen, C Koenen, G Schernthaner Diabetologia 51, 408-416, 2008 | 715 | 2008 |
| Use of twice-daily exenatide in basal insulin–treated patients with type 2 diabetes: a randomized, controlled trial JB Buse, RM Bergenstal, LC Glass, CR Heilmann, MS Lewis, AYM Kwan, ... Annals of internal medicine 154 (2), 103-112, 2011 | 667 | 2011 |
| Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes J Rosenstock, G Dailey, M Massi-Benedetti, A Fritsche, Z Lin, A Salzman Diabetes care 28 (4), 950-955, 2005 | 664 | 2005 |
| Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial G Schernthaner, JL Gross, J Rosenstock, M Guarisco, M Fu, J Yee, ... Diabetes care 36 (9), 2508-2515, 2013 | 663 | 2013 |
| Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial M Davies, L Færch, OK Jeppesen, A Pakseresht, SD Pedersen, ... The Lancet 397 (10278), 971-984, 2021 | 648 | 2021 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials N Sattar, MMY Lee, SL Kristensen, KRH Branch, S Del Prato, NS Khurmi, ... The lancet Diabetes & endocrinology 9 (10), 653-662, 2021 | 629 | 2021 |
| Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial J Rosenstock, C Wysham, JP Frías, S Kaneko, CJ Lee, LF Landó, H Mao, ... The Lancet 398 (10295), 143-155, 2021 | 620 | 2021 |
